دورية أكاديمية
أعرض في EDS

Involvement of Epithelial-Mesenchymal Transition Genes in Small Cell Lung Cancer Phenotypic Plasticity.

التفاصيل البيبلوغرافية
العنوان: Involvement of Epithelial-Mesenchymal Transition Genes in Small Cell Lung Cancer Phenotypic Plasticity.
المؤلفون: Groves SM; Department of Biochemistry, Vanderbilt University, Nashville, TN 37235, USA., Panchy N; Department of Biochemistry & Cellular and Molecular Biology, The University of Tennessee, Knoxville, TN 37996, USA., Tyson DR; Department of Biochemistry, Vanderbilt University, Nashville, TN 37235, USA.; Department of Pharmacology, Vanderbilt University, Nashville, TN 37235, USA., Harris LA; Department of Biomedical Engineering, University of Arkansas, Fayetteville, AR 72701, USA.; Interdisciplinary Graduate Program in Cell and Molecular Biology, University of Arkansas, Fayetteville, AR 72701, USA.; Cancer Biology Program, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA., Quaranta V; Department of Biochemistry, Vanderbilt University, Nashville, TN 37235, USA.; Department of Pharmacology, Vanderbilt University, Nashville, TN 37235, USA., Hong T; Department of Biochemistry & Cellular and Molecular Biology, The University of Tennessee, Knoxville, TN 37996, USA.; National Institute for Mathematical and Biological Synthesis, Knoxville, TN 37996, USA.
المصدر: Cancers [Cancers (Basel)] 2023 Feb 25; Vol. 15 (5). Date of Electronic Publication: 2023 Feb 25.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مستخلص: Small cell lung cancer (SCLC) is an aggressive cancer recalcitrant to treatment, arising predominantly from epithelial pulmonary neuroendocrine (NE) cells. Intratumor heterogeneity plays critical roles in SCLC disease progression, metastasis, and treatment resistance. At least five transcriptional SCLC NE and non-NE cell subtypes were recently defined by gene expression signatures. Transition from NE to non-NE cell states and cooperation between subtypes within a tumor likely contribute to SCLC progression by mechanisms of adaptation to perturbations. Therefore, gene regulatory programs distinguishing SCLC subtypes or promoting transitions are of great interest. Here, we systematically analyze the relationship between SCLC NE/non-NE transition and epithelial to mesenchymal transition (EMT)-a well-studied cellular process contributing to cancer invasiveness and resistance-using multiple transcriptome datasets from SCLC mouse tumor models, human cancer cell lines, and tumor samples. The NE SCLC-A2 subtype maps to the epithelial state. In contrast, SCLC-A and SCLC-N (NE) map to a partial mesenchymal state (M1) that is distinct from the non-NE, partial mesenchymal state (M2). The correspondence between SCLC subtypes and the EMT program paves the way for further work to understand gene regulatory mechanisms of SCLC tumor plasticity with applicability to other cancer types.
References: Genome Biol. 2018 Feb 6;19(1):15. (PMID: 29409532)
Genes Dev. 2015 Aug 1;29(15):1587-92. (PMID: 26215568)
Cell Rep. 2022 Jan 11;38(2):110240. (PMID: 35021086)
Nat Cell Biol. 2009 Dec;11(12):1487-95. (PMID: 19935649)
Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17531-6. (PMID: 23047698)
Cancer Cell. 2020 Jul 13;38(1):60-78.e12. (PMID: 32473656)
Transl Lung Cancer Res. 2018 Feb;7(1):21-31. (PMID: 29535910)
NPJ Syst Biol Appl. 2019 Jun 14;5:21. (PMID: 31275609)
Cell Syst. 2018 Jul 25;7(1):77-91.e7. (PMID: 30007539)
Cell. 2008 May 16;133(4):704-15. (PMID: 18485877)
FASEB J. 2010 Jun;24(6):1838-51. (PMID: 20097873)
Cancer Cell. 2021 Nov 8;39(11):1479-1496.e18. (PMID: 34653364)
Biophys J. 2013 Aug 20;105(4):1079-89. (PMID: 23972859)
Mol Cell Proteomics. 2019 Mar;18(3):576-593. (PMID: 30563849)
Cancer Cell. 2021 Mar 8;39(3):346-360.e7. (PMID: 33482121)
Nature. 2016 Sep 1;537(7618):102-106. (PMID: 27556950)
EMBO Mol Med. 2021 Jan 11;13(1):e13122. (PMID: 33296145)
Sci Signal. 2014 Sep 30;7(345):ra91. (PMID: 25270257)
Nature. 1997 Apr 24;386(6627):852-5. (PMID: 9126746)
Nat Methods. 2015 Mar;12(3):233-5, 3 p following 235. (PMID: 25622107)
J Clin Invest. 2009 Jun;119(6):1420-8. (PMID: 19487818)
Front Genet. 2021 Aug 20;12:719099. (PMID: 34490045)
Cell. 2010 May 14;141(4):559-63. (PMID: 20478246)
Cell Syst. 2022 Sep 21;13(9):690-710.e17. (PMID: 35981544)
Cancer Cell. 2013 Jul 8;24(1):105-19. (PMID: 23792190)
Cancer Res. 2017 Mar 1;77(5):1063-1074. (PMID: 27932399)
Br J Cancer. 2013 Apr 30;108(8):1704-11. (PMID: 23519056)
Transl Lung Cancer Res. 2018 Feb;7(1):32-49. (PMID: 29535911)
Nat Med. 2015 Sep;21(9):989-97. (PMID: 26236989)
Nat Cancer. 2020 Apr;1:423-436. (PMID: 33521652)
Cell. 2018 Jul 26;174(3):716-729.e27. (PMID: 29961576)
PLoS Comput Biol. 2019 Oct 31;15(10):e1007343. (PMID: 31671086)
iScience. 2022 Sep 27;25(10):105224. (PMID: 36248730)
Nat Rev Cancer. 2019 May;19(5):289-297. (PMID: 30926931)
Nat Cell Biol. 2017 May;19(5):518-529. (PMID: 28414315)
Nat Rev Cancer. 2017 Dec;17(12):725-737. (PMID: 29077690)
Cancer Discov. 2012 May;2(5):401-4. (PMID: 22588877)
Cancer Res. 2013 Oct 15;73(20):6299-309. (PMID: 23943797)
Nature. 2017 May 18;545(7654):360-364. (PMID: 28489825)
Cancer Cell. 2011 Feb 15;19(2):244-56. (PMID: 21316603)
Genes Dev. 2022 Mar 1;36(5-6):241-258. (PMID: 35318269)
Nature. 2015 Nov 26;527(7579):472-6. (PMID: 26560033)
Nature. 2018 Apr;556(7702):463-468. (PMID: 29670281)
Cell. 2009 Nov 25;139(5):871-90. (PMID: 19945376)
Nat Commun. 2018 Nov 27;9(1):5005. (PMID: 30479345)
Proc Natl Acad Sci U S A. 2021 May 11;118(19):. (PMID: 33941680)
Nat Commun. 2020 May 1;11(1):2142. (PMID: 32358524)
Hum Cell. 2017 Jan;30(1):1-10. (PMID: 27785690)
EMBO Mol Med. 2014 Sep 11;6(10):1279-93. (PMID: 25214461)
Nature. 2015 Sep 10;525(7568):256-60. (PMID: 26331542)
PLoS Comput Biol. 2015 Nov 10;11(11):e1004569. (PMID: 26554584)
NAR Genom Bioinform. 2022 Sep 21;4(3):lqac072. (PMID: 36159174)
Pathol Int. 2015 Jun;65(6):277-85. (PMID: 25708144)
Nature. 2017 Jun 15;546(7658):431-435. (PMID: 28607484)
Dis Model Mech. 2020 Dec 21;13(12):. (PMID: 33355253)
Proc Natl Acad Sci U S A. 2013 Nov 5;110(45):18144-9. (PMID: 24154725)
Sci Adv. 2021 Oct;7(40):eabg1850. (PMID: 34597132)
Nucleic Acids Res. 2022 Apr 22;50(7):3693-3708. (PMID: 35380686)
PLoS Comput Biol. 2020 Mar 10;16(3):e1007682. (PMID: 32155144)
معلومات مُعتمدة: U01 CA215845 United States CA NCI NIH HHS; U54 CA217450 United States CA NCI NIH HHS; R01 GM140462 United States GM NIGMS NIH HHS; R50 CA243783 United States CA NCI NIH HHS; R01GM140462 United States GM NIGMS NIH HHS; K22CA237857 United States CA NCI NIH HHS; R50CA24378 United States CA NCI NIH HHS; U54CA217450 United States CA NCI NIH HHS
فهرسة مساهمة: Keywords: cellular plasticity; epithelial–mesenchymal transition; single-cell RNA-sequencing; small cell lung cancer
تواريخ الأحداث: Date Created: 20230311 Latest Revision: 20231006
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC10001072
DOI: 10.3390/cancers15051477
PMID: 36900269
قاعدة البيانات: MEDLINE
الوصف
تدمد:2072-6694
DOI:10.3390/cancers15051477